Cite
HARVARD Citation
Harbeck, N. et al. (n.d.). 291ORibociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs). Annals of oncology. p. . [Online].